{"id":"W4200221970","doi":"10.1016/j.annonc.2021.10.154","title":"135P First-in-human phase I trial of SRF617, a potent inhibitor of CD39 activity, as monotherapy or in combination, in patients (pts) with advanced solid tumors","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Adenosine and Purinergic Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":9,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Internal medicine; Nausea; Adverse effect; Combination therapy; Tolerability; Anemia; Gastroenterology; Neutropenia; Toxicity","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007598422,0.001261899,0.001528461,0.0003362151,0.0003293492,0.001031294,0.0005613958,0.0006880822,0.00381093],"category_scores_gemma":[0.0004694638,0.0003464882,0.0009726088,0.0003835678,0.0006750273,0.000564612,0.0003258742,0.002917281,0.0008242072],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009860384,"about_ca_system_score_gemma":0.001521578,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001996624,"about_ca_topic_score_gemma":0.006236163,"domain_scores_codex":[0.9997995,0.00006521167,0.000007844053,0.00002989594,0.00002011706,0.00007729528],"domain_scores_gemma":[0.9997197,0.00003600652,0.0000324506,0.0000149797,0.00001194102,0.0001849296],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5294294,0.03447758,0.007568866,0.001685747,0.002648185,0.0006060263,0.0005028439,0.006704809,0.09585889,0.002499818,0.02111452,0.2969034],"study_design_scores_gemma":[0.5137728,0.4394531,0.01736271,0.00009953686,0.0009686972,0.0008317485,0.0001402647,0.0028127,0.009436964,0.0008794378,0.01417611,0.00006589817],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9861116,0.002973414,0.000661651,0.001105128,0.0002637059,0.001270309,0.002223961,0.0002281897,0.005161964],"genre_scores_gemma":[0.9866355,0.002445698,0.001443362,0.0009703756,0.0001518479,0.0007446069,0.003187744,0.00004314781,0.004377658],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00381093,"threshold_uncertainty_score":0.0127489,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02899490264738615,"score_gpt":0.3682634328552142,"score_spread":0.3392685302078281,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}